Search results
Pages
-
- Time trends in the treatment and survival of 5036 Uveal melanoma patients in The Netherlands over a 30-year period
-
- Real-world outcomes of ipilimumab plus nivolumab combination therapy in a nationwide cohort of advanced melanoma patients in the Netherlands
-
- A survival tree of advanced melanoma patients with brain metastases treated with immune checkpoint inhibitors
-
- Health-state utilities in long-term advanced melanoma survivors comparable with the general population
-
- Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials
-
- Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies
-
- Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma
-
- Trends in incidence and survival of 1496 patients with mucosal melanoma in the Netherlands (1990-2019)
-
- Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma
-
- Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study
-
- Systemic Therapy in Advanced Nodular Melanoma versus Superficial Spreading Melanoma: A Nation-Wide Study of the Dutch Melanoma Treatment Registry